{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T04:30:14Z","timestamp":1654662614127},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,5,21]],"date-time":"2013-05-21T00:00:00Z","timestamp":1369094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,5,21]],"date-time":"2013-05-21T00:00:00Z","timestamp":1369094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1038\/pcan.2013.14","type":"journal-article","created":{"date-parts":[[2013,5,21]],"date-time":"2013-05-21T10:17:31Z","timestamp":1369131451000},"page":"239-247","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The influence of growth hormone\/insulin-like growth factor deficiency on prostatic dysplasia in pbARR2-Cre, PTEN knockout mice"],"prefix":"10.1038","volume":"16","author":[{"given":"K","family":"Takahara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Ibuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Ghaffari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Tearle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C J","family":"Ong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M E","family":"Gleave","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Pollak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M E","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,5,21]]},"reference":[{"key":"BFpcan201314_CR1","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1126\/science.279.5350.563","volume":"279","author":"JM Chan","year":"1998","unstructured":"Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 563\u2013566.","journal-title":"Science"},{"key":"BFpcan201314_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0304-3835(03)00159-9","volume":"195","author":"D LeRoith","year":"2003","unstructured":"LeRoith D, Roberts CT Jr . The insulin-like growth factor system and cancer. Cancer Lett 2003; 195: 127\u2013137.","journal-title":"Cancer Lett"},{"key":"BFpcan201314_CR3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.molmed.2004.12.005","volume":"11","author":"AG Papatsoris","year":"2005","unstructured":"Papatsoris AG, Karamouzis MV, Papavassiliou AG . Novel insights into the implication of the IGF-1 network in prostate cancer. Trends Mol Med 2005; 11: 52\u201355.","journal-title":"Trends Mol Med"},{"key":"BFpcan201314_CR4","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.urolonc.2006.07.019","volume":"25","author":"CJ Ryan","year":"2007","unstructured":"Ryan CJ, Haqq CM, Simko J, Nonaka DF, Chan JM, Weinberg V et al. Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer. Urol Oncol 2007; 25: 134\u2013140.","journal-title":"Urol Oncol"},{"key":"BFpcan201314_CR5","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S0959-8049(00)00102-7","volume":"36","author":"M Pollak","year":"2000","unstructured":"Pollak M . Insulin-like growth factor physiology and cancer risk. Eur J Cancer 2000; 36: 1224\u20131228.","journal-title":"Eur J Cancer"},{"key":"BFpcan201314_CR6","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1073\/pnas.97.7.3455","volume":"97","author":"J DiGiovanni","year":"2000","unstructured":"DiGiovanni J, Kiguchi K, Frijhoff A, Wilker E, Bol DK, Beltran L et al. Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci USA 2000; 97: 3455\u20133460.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFpcan201314_CR7","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1093\/jnci\/94.14.1099","volume":"94","author":"JM Chan","year":"2002","unstructured":"Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002; 94: 1099\u20131106.","journal-title":"J Natl Cancer Inst"},{"key":"BFpcan201314_CR8","doi-asserted-by":"publisher","first-page":"630","DOI":"10.4161\/cbt.2.6.678","volume":"2","author":"A Grimberg","year":"2003","unstructured":"Grimberg A . Mechanisms by which IGF-I may promote cancer. Cancer Biol Ther 2003; 2: 630\u2013635.","journal-title":"Cancer Biol Ther"},{"key":"BFpcan201314_CR9","first-page":"2942","volume":"62","author":"GO Hellawell","year":"2002","unstructured":"Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM . Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 2002; 62: 2942\u20132950.","journal-title":"Cancer Res"},{"key":"BFpcan201314_CR10","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/pros.10186","volume":"54","author":"A Scorilas","year":"2003","unstructured":"Scorilas A, Plebani M, Mazza S, Basso D, Soosaipillai AR, Katsaros N et al. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA. Prostate 2003; 54: 220\u2013229.","journal-title":"Prostate"},{"key":"BFpcan201314_CR11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1158\/1055-9965.EPI-03-0102","volume":"13","author":"SE Oliver","year":"2004","unstructured":"Oliver SE, Barrass B, Gunnell DJ, Donovan JL, Peters TJ, Persad RA et al. Serum insulin-like growth factor-I is positively associated with serum prostate-specific antigen in middle-aged men without evidence of prostate cancer. Cancer Epidemiol Biomarkers Prev 2004; 13: 163\u2013165.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"BFpcan201314_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/13813450801969715","volume":"114","author":"F Frasca","year":"2008","unstructured":"Frasca F, Pandini G, Sciacca L, Pezzino V, Squatrito S, Belfiore A et al. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 2008; 114: 23\u201337.","journal-title":"Arch Physiol Biochem"},{"key":"BFpcan201314_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1046\/j.1464-410X.2003.04061.x","volume":"91","author":"GO Hellawell","year":"2003","unstructured":"Hellawell GO, Ferguson DJ, Brewster SF, Macaulay VM . Chemosensitization of human prostate cancer using antisense agents targeting the type 1 insulin-like growth factor receptor. BJU Int 2003; 91: 271\u2013277.","journal-title":"BJU Int"},{"key":"BFpcan201314_CR14","doi-asserted-by":"publisher","first-page":"8620","DOI":"10.1158\/0008-5472.CAN-04-2446","volume":"64","author":"SL Krueckl","year":"2004","unstructured":"Krueckl SL, Sikes RA, Edlund NM, Bell RH, Hurtado-Coll A, Fazli L et al. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 2004; 64: 8620\u20138629.","journal-title":"Cancer Res"},{"key":"BFpcan201314_CR15","first-page":"6276","volume":"61","author":"T Nickerson","year":"2001","unstructured":"Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL, Pollak M . In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 2001; 61: 6276\u20136280.","journal-title":"Cancer Res"},{"key":"BFpcan201314_CR16","first-page":"215","volume":"58","author":"H Huynh","year":"1998","unstructured":"Huynh H, Seyam RM, Brock GB . Reduction of ventral prostate weight by finasteride is associated with suppression of insulin-like growth factor I (IGF-I) and IGF-I receptor genes and with an increase in IGF binding protein 3. Cancer Res 1998; 58: 215\u2013218.","journal-title":"Cancer Res"},{"key":"BFpcan201314_CR17","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1158\/0008-5472.CAN-04-1837","volume":"65","author":"G Pandini","year":"2005","unstructured":"Pandini G, Mineo R, Frasca F, Roberts CT Jr, Marcelli M, Vigneri R et al. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res 2005; 65: 1849\u20131857.","journal-title":"Cancer Res"},{"key":"BFpcan201314_CR18","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1210\/er.2009-0010","volume":"30","author":"C Ohlsson","year":"2009","unstructured":"Ohlsson C, Mohan S, Sjogren K, Tivesten A, Isgaard J, Isaksson O et al. The role of liver-derived insulin-like growth factor-I. Endocr Rev 2009; 30: 494\u2013535.","journal-title":"Endocr Rev"},{"key":"BFpcan201314_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0305-0491(98)10106-2","volume":"121","author":"AA Butler","year":"1998","unstructured":"Butler AA, Yakar S, Gewolb IH, Karas M, Okubo Y, LeRoith D . Insulin-like growth factor-I receptor signal transduction: at the interface between physiology and cell biology. Comp Biochem Physiol B 1998; 121: 19\u201326.","journal-title":"Comp Biochem Physiol B"},{"key":"BFpcan201314_CR20","doi-asserted-by":"publisher","first-page":"8351","DOI":"10.1158\/1078-0432.CCR-04-0130","volume":"10","author":"GV Thomas","year":"2004","unstructured":"Thomas GV, Horvath S, Smith BL, Crosby K, Lebel LA, Schrage M et al. Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer. Clin Cancer Res 2004; 10: 8351\u20138356.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"BFpcan201314_CR21","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1038\/sj.pcan.4500457","volume":"3","author":"M Muller","year":"2000","unstructured":"Muller M, Rink K, Krause H, Miller K . PTEN\/MMAC1 mutations in prostate cancer. Prostate Cancer Prostatic Dis 2000; 3 (Suppl 1): S32.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"BFpcan201314_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1371\/journal.pbio.0000059","volume":"1","author":"LC Trotman","year":"2003","unstructured":"Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A et al. Pten dose dictates cancer progression in the prostate. PLoS Biol 2003; 1: 27.","journal-title":"PLoS Biol"},{"key":"BFpcan201314_CR23","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/pros.21268","volume":"71","author":"K Takahara","year":"2011","unstructured":"Takahara K, Tearle H, Ghaffari M, Gleave ME, Pollak M, Cox ME . Human prostate cancer xenografts in lit\/lit mice exhibit reduced growth and androgen-independent progression. Prostate 2011; 71: 525\u2013537.","journal-title":"Prostate"},{"key":"BFpcan201314_CR24","doi-asserted-by":"publisher","first-page":"5246","DOI":"10.1073\/pnas.95.9.5246","volume":"95","author":"YE Whang","year":"1998","unstructured":"Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL et al. Inactivation of the tumor suppressor PTEN\/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 1998; 95: 5246\u20135250.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFpcan201314_CR25","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1038\/modpathol.2008.96","volume":"21","author":"M Yoshimoto","year":"2008","unstructured":"Yoshimoto M, Joshua AM, Cunha IW, Coudry RA, Fonseca FP, Ludkovski O et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol 2008; 21: 1451\u20131460.","journal-title":"Mod Pathol"},{"key":"BFpcan201314_CR26","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1535-6108(03)00215-0","volume":"4","author":"S Wang","year":"2003","unstructured":"Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003; 4: 209\u2013221.","journal-title":"Cancer Cell"},{"key":"BFpcan201314_CR27","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.ccr.2011.05.006","volume":"19","author":"DJ Mulholland","year":"2011","unstructured":"Mulholland DJ, Tran LM, Li Y, Cai H, Morim A, Wang S et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 2011; 19: 792\u2013804.","journal-title":"Cancer Cell"},{"key":"BFpcan201314_CR28","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S1074-7613(01)00134-0","volume":"14","author":"A Suzuki","year":"2001","unstructured":"Suzuki A, Yamaguchi MT, Ohteki T, Sasaki T, Kaisho T, Kimura Y et al. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 2001; 14: 523\u2013534.","journal-title":"Immunity"},{"key":"BFpcan201314_CR29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0925-4773(00)00551-7","volume":"101","author":"X Wu","year":"2001","unstructured":"Wu X, Wu J, Huang J, Powell WC, Zhang J, Matusik RJ et al. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev 2001; 101: 61\u201369.","journal-title":"Mech Dev"},{"key":"BFpcan201314_CR30","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/ng0793-227","volume":"4","author":"P Godfrey","year":"1993","unstructured":"Godfrey P, Rahal JO, Beamer WG, Copeland NG, Jenkins NA, Mayo KE . GHRH receptor of little mice contains a missense mutation in the extracellular domain that disrupts receptor function. Nat Genet 1993; 4: 227\u2013232.","journal-title":"Nat Genet"},{"key":"BFpcan201314_CR31","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1158\/0008-5472.CAN-09-2377","volume":"70","author":"M Moussavi","year":"2010","unstructured":"Moussavi M, Fazli L, Tearle H, Guo Y, Cox M, Bell J et al. Oncolysis of prostate cancers induced by vesicular stomatitis virus in PTEN knockout mice. Cancer Res 2010; 70: 1367\u20131376.","journal-title":"Cancer Res"},{"key":"BFpcan201314_CR32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1371\/journal.pone.0003940","volume":"3","author":"HA Luchman","year":"2008","unstructured":"Luchman HA, Benediktsson H, Villemaire ML, Peterson AC, Jirik FR . The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision. PLoS One 2008; 3: 15.","journal-title":"PLoS One"},{"key":"BFpcan201314_CR33","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1158\/0008-5472.CAN-11-3132","volume":"72","author":"DJ Mulholland","year":"2012","unstructured":"Mulholland DJ, Kobayashi N, Ruscetti M, Zhi A, Tran LM, Huang J et al. Pten loss and RAS\/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem\/progenitor cells. Cancer Res 2012; 72: 1878\u20131889.","journal-title":"Cancer Res"},{"key":"BFpcan201314_CR34","doi-asserted-by":"publisher","first-page":"4736","DOI":"10.1038\/sj.onc.1208572","volume":"24","author":"N Majeed","year":"2005","unstructured":"Majeed N, Blouin MJ, Kaplan-Lefko PJ, Barry-Shaw J, Greenberg NM, Gaudreau P et al. A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model. Oncogene 2005; 24: 4736\u20134740.","journal-title":"Oncogene"},{"key":"BFpcan201314_CR35","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/pros.21054","volume":"70","author":"J Furukawa","year":"2010","unstructured":"Furukawa J, Wraight CJ, Freier SM, Peralta E, Atley LM, Monia BP et al. Antisense oligonucleotide targeting of insulin-like growth factor-1 receptor (IGF-1R) in prostate cancer. Prostate 2010; 70: 206\u2013218.","journal-title":"Prostate"},{"key":"BFpcan201314_CR36","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1158\/0008-5472.CAN-07-3165","volume":"68","author":"M Anzo","year":"2008","unstructured":"Anzo M, Cobb LJ, Hwang DL, Mehta H, Said JW, Yakar S et al. Targeted deletion of hepatic Igf1 in TRAMP mice leads to dramatic alterations in the circulating insulin-like growth factor axis but does not reduce tumor progression. Cancer Res 2008; 68: 3342\u20133349.","journal-title":"Cancer Res"},{"key":"BFpcan201314_CR37","doi-asserted-by":"publisher","first-page":"276","DOI":"10.2353\/ajpath.2009.080086","volume":"174","author":"M Szabolcs","year":"2009","unstructured":"Szabolcs M, Keniry M, Simpson L, Reid LJ, Koujak S, Schiff SC et al. Irs2 inactivation suppresses tumor progression in Pten+\/\u2212 mice. Am J Pathol 2009; 174: 276\u2013286.","journal-title":"Am J Pathol"},{"key":"BFpcan201314_CR38","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2174\/138620706776055449","volume":"9","author":"AV Schally","year":"2006","unstructured":"Schally AV, Varga JL . Antagonists of growth hormone-releasing hormone in oncology. Comb Chem High Throughput Screen 2006; 9: 163\u2013170.","journal-title":"Comb Chem High Throughput Screen"},{"key":"BFpcan201314_CR39","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/pros.20262","volume":"64","author":"A Stangelberger","year":"2005","unstructured":"Stangelberger A, Schally AV, Varga JL, Hammann BD, Groot K, Halmos G et al. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin\/gastrin releasing peptide (BN\/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF\/HER family in PC-3 and DU-145 human androgen-independent prostate cancers. Prostate 2005; 64: 303\u2013315.","journal-title":"Prostate"},{"key":"BFpcan201314_CR40","doi-asserted-by":"publisher","first-page":"e12445","DOI":"10.1371\/journal.pone.0012445","volume":"5","author":"D Kong","year":"2010","unstructured":"Kong D, Banerjee S, Ahmad A, Li Y, Wang Z, Sethi S et al. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One 2010; 5: e12445.","journal-title":"PLoS One"},{"key":"BFpcan201314_CR41","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.bone.2010.07.023","volume":"48","author":"G van der Pluijm","year":"2011","unstructured":"van der Pluijm G . Epithelial plasticity, cancer stem cells and bone metastasis formation. Bone 2011; 48: 37\u201343.","journal-title":"Bone"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/pcan201314.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/pcan201314","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/pcan201314.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T21:36:00Z","timestamp":1648676160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/pcan201314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,21]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["BFpcan201314"],"URL":"https:\/\/doi.org\/10.1038\/pcan.2013.14","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,21]]},"assertion":[{"value":"17 January 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}